

**PATIENT INFORMATION**  
**QULIPTA® (kew-LIP-tah)**  
(atogepant)  
tablets, for oral use

**What is QULIPTA?**

- QULIPTA is a prescription medicine used for the preventive treatment of migraine in adults.

It is not known if QULIPTA is safe and effective in children.

**Do not take QULIPTA if you:**

- have had an allergic reaction to atogepant or any ingredients in QULIPTA. See the end of this Patient Information leaflet for a complete list of ingredients in QULIPTA.

**Before you take QULIPTA tell your healthcare provider about all of your medical conditions, including if you:**

- have high blood pressure.
- have circulation problems in your fingers and toes.
- have kidney problems or are on dialysis.
- have liver problems.
- are pregnant or plan to become pregnant. It is not known if QULIPTA will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if QULIPTA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking QULIPTA.

**Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other medicines.

Keep a list of medicines you take to show to your healthcare provider or pharmacist when you get a new medicine.

**How should I take QULIPTA?**

- Take QULIPTA by mouth with or without food.
- Take QULIPTA exactly as your healthcare provider tells you to take it.

**What are the possible side effects of QULIPTA?**

**QULIPTA can cause serious side effects, including:**

- **Allergic (hypersensitivity) reactions, including anaphylaxis:** Serious allergic reactions can happen when you take QULIPTA or days after. Stop taking QULIPTA and get emergency medical help right away if you get any of the following symptoms, which may be part of a serious allergic reaction:
  - swelling of the face, lips, or tongue
  - trouble breathing
  - rash
  - itching
  - hives
- **High blood pressure:** High blood pressure or worsening of high blood pressure can happen when you take QULIPTA. Contact your healthcare provider if you have an increase in blood pressure.
- **Raynaud's phenomenon:** A type of circulation problem can worsen or happen when you take QULIPTA. Raynaud's phenomenon can lead to your fingers or toes feeling numb, cool, or painful, or changing color from pale, to blue, to red. Contact your healthcare provider if these symptoms occur.

**The most common side effects of QULIPTA include:** nausea, constipation, and fatigue/sleepiness.

These are not all of the possible side effects of QULIPTA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store QULIPTA?**

- Store QULIPTA at room temperature between 68°F to 77°F (20°C to 25°C).

**Keep QULIPTA and all medicines out of the reach of children.**

**General information about the safe and effective use of QULIPTA.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use QULIPTA for a condition for which it was not prescribed. Do not give QULIPTA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about QULIPTA that is written for health professionals.

**What are the ingredients in QULIPTA?**

**Active ingredient:** atogepant

**Inactive ingredients:** colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.

Manufactured for:

AbbVie Inc.

North Chicago, IL 60064

© 2025 AbbVie. All rights reserved.

QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.

This Patient Information has been approved by the U.S. Food and Drug Administration  
20091381

Revised: 3/2025